Advisory Board July 9, 2024

By: Natalie Trebes, Vidal Seegobin, Susan McDonald, and Max Hakanson

The Supreme Court of the United States (SCOTUS) recently overturned the Chevron doctrine, which required courts to defer to federal agencies’ interpretation of ambiguous laws. Advisory Board’s Natalie Trebes, Vidal Seegobin, Susan McDonald, and Max Hakanson explain how this could impact healthcare and highlight what they’ll be watching in the post-Chevron era.

Bold predictions for healthcare in 2024

SCOTUS’ Chevron decision

In a 6-3 decision, SCOTUS overturned the Chevron doctrine on June 28, repealing a 40-year-old legal precedent that required courts to defer to regulatory agencies to interpret ambiguous laws.

Since Chevron v. Natural Resources Defense Council was decided in 1984, it has become one of the...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Govt Agencies, Regulations
Chinese medical devices are in health systems across U.S., and the government and hospitals are worried
DOGE cuts at health agencies prompt 'brain drain' fears
Selling a practice: How to remain HIPAA compliant during a sale
On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval
Federal health, research firings draw alarm: ‘Every American should be outraged’

Share This Article